GENESIS Ventures

Renalyse, operating under the trade name of CreatSens Health S.L., is a biotechnology company that specializes in developing point-of-care decentralized diagnostic devices. These innovative tools facilitate the analysis of key biochemical parameters in blood, allowing for decentralized monitoring of significant biomarkers such as creatinine and potassium, which are crucial for managing chronic kidney disease. By utilizing a paper sensor, Renalyse's devices provide timely results, enabling users to predict and detect acute conditions from the comfort of their homes. This approach aims to enhance the management of chronic kidney disease through early intervention and improved health monitoring.

Corify Care SL is a medical technology company based in Madrid, Spain, focused on improving the treatment of atrial fibrillation through its innovative non-invasive electrocardiographic imaging device, ACORYS. This device allows healthcare professionals to visualize the electrical activity of the heart in real time without the need for invasive procedures, such as catheters or complex imaging techniques like MRI or CT scans. By addressing the limitations of existing solutions, ACORYS enhances the clinical management of cardiac arrhythmias, enabling accurate mapping and identification of optimal treatment strategies for patients. The technology has the potential to benefit over 10 million atrial fibrillation patients in Europe alone. Established in 2019, Corify Care is backed by leading experts in cardiac arrhythmias, positioning it as a promising player in the medical device sector.

ABLE Human Motion is a Barcelona-based medical device start-up founded in 2018 that specializes in the development of robotic exoskeletons designed to improve mobility for individuals with disabilities. The company's primary product, the ABLE Exoskeleton, is a lightweight and user-friendly wearable device that assists paraplegic users in standing, walking, and sitting. This innovative technology employs a motor and gearbox to mimic muscle movement, along with an inertial sensor to interpret the user's intentions. ABLE Human Motion aims to enhance the quality of life for wheelchair users by promoting greater independence and mobility while also providing rehabilitation tools for clinicians to improve treatment efficiency.

Mowoot is a company that specializes in developing non-pharmacological and non-invasive solutions for individuals suffering from chronic constipation. It offers a wearable medical device that delivers an automatic, colon-specific massage, mimicking the manual abdominal massage typically performed by healthcare professionals. Utilizing advanced pneumatic technology, Mowoot's device aims to treat and prevent chronic slow transit constipation without the need for colon cleansing supplements, enemas, or laxatives. Founded in 2014 and based in Barcelona, Spain, Mowoot emerged from the MOEBIO dHEALTH program, which draws inspiration from innovative design and business methodologies. The company's mission is to enhance the quality of life for those affected by chronic constipation through its unique and effective approach.

Quality Pharma specializes in developing advanced AI-powered medication evaluation tools, particularly its proprietary QS System® ("Quantum Satis"). This innovative software serves as a clinical decision support system, designed to enhance the safety and efficacy of medication-based treatments. By utilizing a unique algorithm, Quantum Satis identifies potential adverse drug events in patients undergoing polypharmacy, thereby diagnosing issues such as inappropriate drugs, drug duplication, and drug-drug interactions. The system features modules for analysis, monitoring, and evaluation, making it a valuable resource for healthcare providers and pharma professionals. Additionally, Quality Pharma offers a user-friendly interactive version of the QS System for patients and their caregivers, empowering them to identify and address potential drug-related problems swiftly. Ultimately, Quality Pharma aims to improve the health and quality of life for elderly patients through better medication management.

NeuroHeal is a spinout from the Institut of Neurosciences from the Autonomous University of Barcelona.

ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.